Chardan Capital Maintains Buy on Regenxbio, Lowers Price Target to $90
Chardan Capital analyst Geulah Livshits maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $100 to $90.
SVB Leerink Maintains Market Perform on Regenxbio, Lowers Price Target to $43
SVB Leerink analyst Mani Foroohar maintains Regenxbio (NASDAQ:RGNX) with a Market Perform and lowers the price target from $44 to $43.
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell
• Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.
Earnings Outlook For Regenxbio
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Tuesday, 2021-11-02. Here's what investors need to know before the announcement.
Analysts estimate that Regenxbio will likely report an Earnings Per Share (EPS) of $-1.08
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
Regenxbio Reveals Interim Data From Diabetic Retinopathy Gene Therapy Trial
Regenxbio Inc (NASDAQ:RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involved diabetic…
REGENXBIO Saturday Morning Highlighted Presentation Of Initial Data From Phase 2 ALTITUDE Trial Of RGX-314 For Treatment Of Diabetic Retinopathy Using Suprachoroidal Delivery At American Society Of Retina Specialists Meeting
Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious adverse events
No intraocular inflammation observed
Positive interim data update from Cohort 1 at
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets amid the broader market strength.
44 Biggest Movers From Yesterday
Gainers
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary endpoints.